Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c

November 12, 2019 4:36 PM EST

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $567 thousand versus the consensus estimate of $810 thousand.

New Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last VisitImplemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020Received CE Mark Approval for Renevia®; Working to Identify European Commercial PartnerConducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net ProceedsStrengthened... More